Latest Conference Articles
Stay up to date on the latest oncology and nursing conferences.
Preliminary Results Show Novel Combo Appears Safe in High-Risk Non-Muscle-Invasive Bladder Cancer
July 17th 2021, 3:00pm
Preliminary study results recently presented at the 2021 European Association of Urology Congress demonstrate that the safety profile of the combination of Bacillus Calmette-Guérin (BCG) and mitomycin is comparable to BCG alone.
New ASCO Guideline Recommends Adjuvant Olaparib for Patients with Hereditary Breast Cancer
June 30th 2021, 6:00pm
ASCO updated its guidelines following a presentation of the OlympiA trial presented at its 2021 Annual Meeting.
Texas Study Demonstrates Need for Electronic Patient-Report Outcomes in Oncology Centers
June 25th 2021, 2:30pm
A presentation at the 2021 American Society of Clinical Oncology Meeting demonstrated that the use of electronic patient-reported outcomes in community oncology centers improved symptom-management.
Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma Report Improved PFS with Frontline Toripalimab Plus Gemcitabine/Cisplatin
June 22nd 2021, 3:00pm
Data from the phase 3 JUPITER-02 trial (NCT03581786) suggests that frontline toripalimab plus gemcitabine/cisplatin improves progression-free survival (PFS).
Patients With Advanced ESCC Experience Improved Survival Outcomes With Addition of Nivolumab to Ipilimumab or Chemotherapy
June 21st 2021, 6:00pm
Survival outcomes in the frontline treatment of patients with unresectable advanced or metastatic esophageal squamous cell carcinoma were improved when nivolumab was added alongside either ipilimumab or chemotherapy.
Triage Care Management Tool Associated with 8% Hospital Avoidance
June 21st 2021, 2:30pm
A Texas study revealed that the implementation of electronic patient management solutions resulted in reduced call back times for symptom-related calls as well as reduced hospitalizations.
Patient Characteristics Linked to Time on Treatment and Survival in Patients With mCRC Receiving Cetuximab
June 11th 2021, 6:26pm
KRAS mutational status and geographical region were associated with time on treatment (TOT), and body mass index (BMI) and age were linked with overall survival (OS) in patients with metastatic colorectal cancer mCRC) being treated with second-line cetuximab (Erbitux) after irinotecan or oxaliplatin-based regimens.
Cabozantinib Associated With Higher Rates of Certain AEs in Advanced Kidney Cancer
June 11th 2021, 1:28pm
While cabozantinib exposure was not a predictor of progression-free survival, it was related to high rate of palmar-plantar plantar erythrodysesthesia and diarrhea in patients with advanced renal cell carcinoma who are given frontline cabozantinib plus nivolumab.
Nurses Have the Responsibility to be the ‘Voice of the Patient’ in Palliative Care Advocacy
June 9th 2021, 6:43pm
Learn how to approach palliative care discussions with both physicians and patients.